Composition and delivery system

A technology of a delivery system and a composition, which is applied in the field of delivering reagents to the subject's target in the delivery system of a stent, can solve problems such as hindering development, and achieve the effect of avoiding release distribution

Inactive Publication Date: 2016-06-08
勒柯特生物有限公司
View PDF6 Cites 39 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In particular, obtaining the desired release profi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition and delivery system
  • Composition and delivery system
  • Composition and delivery system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0134] Example 1: Melt entrapment of microparticles within thermoset PLGA / PEG particles

[0135] 1. Preparation of PLGA / PEG sheet:

[0136] 1.1 Weigh out 2.5 g of PLGA / PEG particles (<100 micron in size and containing 6.5% w / w or 8% w / w of 400 Da PEG) into a weighboat.

[0137] 1.2 Weigh 0.278 g (i.e. 10% w / w of the total combined mass) of PLGA "placebo" particles (20-50 micron diameter spherical particles) in a separate weighing boat, after which PLGA / PEG particles are added and wiped with a wipe. Knife to mix well.

[0138] 1.3 Pour the contents of the weighing boat onto the PTFE sheet and flatten with a spatula to a continuous granular layer of approximately 2mm depth (Figure 1).

[0139] 1.4 Put the PTFE sheet into an oven at 50°C for about 6 hours. Transparent flakes of PLGA / PEG will form.

[0140] 2. Preparation of thermosetting PLGA / PEG blend particles containing placebo particles

[0141] 2.1 Cut the polymer sheet into pieces smaller than 2 x 2 cm using scissors. ...

Embodiment 2

[0148] Example 2. Reduction of Cmax: Release Studies

[0149] Comparison of drug-loaded PLGA microparticle formulations:

[0150] This example shows a comparison of microparticles (MP) with MP trapped in the scaffold of PLGA / PEG particles versus particles made by melt blending MP into PLGA / PEG.

[0151] For better controlled drug release by reducing the initial "burst" effect inherent in polymer controlled release systems, model actives are incorporated into the stent. Burst release can be significantly reduced by a formulation strategy using prednisolone-loaded polymer microspheres incorporated in the scaffold as shown.

[0152] method:

[0153] Prednisolone-bound PLGA particles were manufactured using the following solid dispersion emulsion method:

[0154] A 1 liter batch of a solution of 0.3% (w / v) PVA in distilled water was completely dissolved overnight on a magnetic stirrer set at about 200 rpm. Prior to use, the PVA solution was passed through a 0.2 micron filt...

Embodiment 3

[0168] Embodiment 3: Release (mwt408, logP6.85) of oil red-O as model lipophilic drug

[0169] Purpose:

[0170] To determine the release profile over time of microparticles (MPs) from oil red-O (ORO) loading and compare the release rates of small (20-30 micron) MPs with larger (50-100 micron) MPs.

[0171] It was also to determine if incorporation into PLGA / PEG scaffolds would reduce burst release and provide more sustained release over time.

[0172] method:

[0173] The PLGA / PEG blend used was made by incorporating 8% of PEG400 into PLGA85:15 (LP671). PLGA microparticles were prepared using the DCM emulsion method and using 1% ORO loading in the microparticles. Each 50 mg granule therefore contains a maximum of 500 mg of drug.

[0174] Bracket Manufacturing:

[0175] 300 mg of PLGA / 8% PEG particles in the 100-200 micron size fraction were weighed into a weighing boat and 100 mg of OROMP was added and mixed by hand.

[0176] 320ml of liquid carrier (1% pluronics ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Glass transition temperatureaaaaaaaaaa
Sizeaaaaaaaaaa
Sizeaaaaaaaaaa
Login to view more

Abstract

An injectable agent delivery system comprising a composition that comprises: an agent for sustained delivery located within discrete particles,and an injectable scaffold material comprising discrete particles which are capable of interacting to form a scaffold, and uses thereof.

Description

technical field [0001] The present invention relates to an injectable stent and the use of the stent in a delivery system to deliver an agent to a target site (target site) of a subject (subject, subject). Background technique [0002] Many opportunities exist in the field of regenerative medicine for new clinical treatments that promote tissue repair by localizing agents, such as growth factors, or cells at specific locations within a patient. Examples of clinical opportunities include regeneration of myocardium following infarction, induction of bone growth in spinal fusion, healing of diabetic foot ulcers, and limitation or perhaps reversal of damage due to stroke. Localization of agents, such as growth factors, can be achieved using scaffolds. Scaffolds provide the appropriate mechanical environment, framework and surface chemistry for angiogenesis and tissue formation. The use of scaffolds as drug or cell delivery systems has great potential, but due to the need to ad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L27/50
CPCA61L27/50A61L27/54A61L2300/602A61L2400/06A61P1/02A61P1/04A61P1/16A61P13/00A61P13/02A61P13/10A61P13/12A61P15/08A61P17/02A61P19/00A61P21/00A61P21/04A61P25/00A61P25/14A61P25/16A61P25/28A61P27/02A61P35/00A61P9/00A61P9/10A61P9/14A61P3/10A61L27/18A61L27/56A61L2300/216
Inventor 罗宾·安德鲁·夸克海伦·西利亚·考克斯凯文·莫里斯·谢克谢夫
Owner 勒柯特生物有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap